Caroline Seymour

Managing Editor, OncLive®
Caroline Seymour is your initial point of contact for the OncLive® podcast, OncLive On Air™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com

Articles

UGN-102 Redefines Treatment Standards for Low-Grade, Intermediate-Risk NMIBC

August 27th 2025

William C. Huang, MD, discusses the FDA approval of UGN-102 for the treatment of patients with recurrent, low-grade, intermediate-risk NMIBC.

EMA Grants Orphan Drug Designation to Pegtarazimod for GVHD

August 23rd 2025

Pegtarazimod has received orphan drug designation from the European Medicines Agency for the management of graft-vs-host disease.

Evolving Treatment Strategies Reshape the Landscape of Hematologic Malignancies

August 22nd 2025

Naseema Gangat, MBBS, details updates, novel strategies, and factors that inform decision-making in clinical for patients with hematologic malignancies.

Fruquintinib Efficacy Data Support Its Use in the Third-Line Advanced CRC Setting

August 20th 2025

John Marshall, MD, discusses fruquintinib’s efficacy in later-line CRC, advocating for the agent’s use as maintenance therapy to avoid overtreatment.

FDA Approves MMR IHC Panel pharmDx as a Companion Diagnostic for Nivolumab/Ipilimumab in MSI-H/dMMR CRC

August 20th 2025

The FDA has approved the MMR IHC Panel pharmDx to determine eligibility for nivolumab/ipilimumab in patients with MSI-H/dMMR colorectal cancer.

Health Canada Approves Nivolumab Plus Ipilimumab for Unresectable MSI-H/dMMR CRC and Unresectable HCC

August 20th 2025

Nivolumab plus ipilimumab earned approval from Health Canada for select patients with unresectable colorectal cancer and hepatocellular carcinoma.

Novocure Files Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer

August 20th 2025

The FDA has received a premarket approval application supported by positive results from the PANOVA-3 trial for Tumor Treating Fields (TTFields)—electric fields that exert physical forces to kill cancer cells via a variety of mechanisms—for locally advanced pancreatic cancer.

Removal of REMS Requirements Improves Access to CAR T-Cell Therapy Across Hematologic Malignancies

August 18th 2025

Four expert hematologists discuss the FDA’s decision to remove REMS programs for CD19- and BCMA-directed CAR T-cell therapies in hematologic malignancies.

Thoracic Oncology Fellows Forum Is Highlighted by PRO Data and Tarlatamab in SCLC

August 18th 2025

Hematology/oncology fellows shared insights on notable presentations given during the OncLive Fellows Forum on Thoracic Oncology.

Phase 2/3 Trial Further Evaluates Ficerafusp Alfa With Pembrolizumab in HPV– Head and Neck Cancer

August 18th 2025

Kevin Harrington, MBBS, MRCP, FRCR, FRCP, PhD, DIC, discusses ficerafusp alfa for the treatment of patients with HPV-negative head and neck cancer.

Working Smarter to Unpack the Challenges of a New Cancer Diagnosis

August 16th 2025

Ashish Saxena, MD, PhD, discusses how fellows can make the discussion of an initial cancer diagnosis as productive as possible for patients.

Understanding Hematology/Oncology Clinical Trials Is Crucial to Patient Communication

August 15th 2025

Matthew Hadfield, DO, discusses how hematology/oncology fellows should approach the interpretation of clinical trial data.

SHR-A1811 Monotherapy Generates Similar pCR Rate as PCbHP in HER2+ Breast Cancer

August 14th 2025

The antibody-drug conjugate SHR-A1811 demonstrated a comparable pCR rate to SHR-A1811/pyrotinib and PCbHP in HER2-positive breast cancer.

FDA Grants Fast Track Designation to HLD-0915 for Metastatic Castration-Resistant Prostate Cancer

August 14th 2025

HLD-0915 has received fast track designation from the FDA, allowing for more frequent communication with the agency regarding the drug’s candidacy for approval.

Dr Somaiah on Mutation-Specific Therapy in Gastrointestinal Stromal Tumors

August 13th 2025

Neeta Somaiah, MD, discusses the landscape of mutation-specific therapy for the treatment of patients with a gastrointestinal stromal tumor.

Phase 3 Evaluation of Sigvotatug Vedotin Is Underway in Pretreated Nonsquamous NSCLC

August 13th 2025

Sigvotatug vedotin is being compared with docetaxel in patients with pretreated NSCLC in the phase 3 Be6A Lung-01 study.

CD19 t-haNK Leads to Complete Responses in Waldenstrom Macroglobulinemia

August 13th 2025

CD19 t-haNK demonstrated complete responses in 2 patients with heavily pretreated Waldenstrom macroglobulinemia.

Health Canada Authorizes Perioperative Pembrolizumab in Resectable, Locally Advanced HNSCC

August 13th 2025

Perioperative pembrolizumab has received the green light for use in combination with radiotherapy with or without cisplatin in PD-L1–positive HNSCC.

Fulzerasib Displays Efficacy and Tolerability in KRAS G12C–Mutated Metastatic CRC

August 11th 2025

Fulzerasib monotherapy was safe and active in KRAS G12C–mutated metastatic colorectal cancer.

Dr Sanborn on Early Efficacy and Safety Data With Sigvotatug Vedotin Plus Pembrolizumab in NSCLC

August 8th 2025

Rachel E. Sanborn, MD, discusses preclinical and early clinical data supporting the use of the IB6-directed ADC sigvotatug vedotin in patients with NSCLC.